Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: Experimental study in a murine model of ovarian cancer

Gynecologic Oncology

Volumn 122, Issue 3, 2011, Pages 632-640

  Colombo, Pierre Emmanuel ^a,b   Boustta, Mahfoud ^b   Poujol, Sylvain ^a   Jarlier, Marta ^a   Bressolle, Françoise ^a,b   Teulon, Isabelle ^a   Ladjemi, Maha Zohra ^a   Pinguet, Frederic ^a   Rouanet, Philippe ^a   Vert, Michel ^b  

^a CENTRE VAL D AURELLE   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Bioluminescence imaging; Intraperitoneal chemotherapy; Ovarian cancer; Peritoneal carcinomatosis; Polymer; Prodrug

Indexed keywords

DOXORUBICIN; DRUG CARRIER; POLY(LEVO LYSINE CITRAMIDE); POLYLYSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MODEL; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME;

ADENOCARCINOMA; ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LUMINESCENT MEASUREMENTS; MICE; MICE, INBRED BALB C; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; POLYLYSINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80051547640     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.05.032     Document Type: Article

References (47)

1. S.A. Cannistra Cancer of the ovary N Engl J Med 351 2004 2519 2529
2. P.E. Colombo, A. Mourregot, M. Fabbro, M. Gutowski, B. Saint-Aubert, and F. Quenet Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients Eur J Surg Oncol 35 2009 135 143
3. J. Pfisterer, A. du Bois, U. Wagner, J. Quaas, J.U. Blohmer, and D. Wallwiener Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group Gynecol Oncol 92 2004 949 956 (Pubitemid 38251401)
4. R.L. Dedrick Theoretical and experimental bases of intraperitoneal chemotherapy Semin Oncol 12 1985 1 6 (Pubitemid 16222022)
5. M. Markman Intraperitoneal antineoplastic drug delivery: rationale and results Lancet Oncol 4 2003 277 283 (Pubitemid 36603295)
6. V.J. Verwaal, S. van Ruth, E. de Bree, G.W. van Slooten, H. van Tinteren, and H. Boot Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer J Clin Oncol 21 2003 3737 3743 (Pubitemid 46606227)
7. D.S. Alberts, P.Y. Liu, E.V. Hannigan, R. O'Toole, S.D. Williams, and J.A. Young Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage iii ovarian cancer N Engl J Med 335 1996 1950 1955 (Pubitemid 26428219)
8. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, and S. Lele Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43 (Pubitemid 43048949)
9. J.L. Walker, D.K. Armstrong, H.Q. Huang, J. Fowler, K. Webster, and R.A. Burger Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study Gynecol Oncol 100 2006 27 32 (Pubitemid 41815045)
10. H. Araki, T. Tani, and M. Kodama Antitumor effect of cisplatin incorporated into polylactic acid microcapsules Artif Organs 23 1999 161 168 (Pubitemid 29081346)
11. R. Duncan Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway? Pharm Sci Technol Today 2 1999 441 449 (Pubitemid 29528143)
12. K. Ulbrich, T. Etrych, P. Chytil, M. Pechar, M. Jelinkova, and B. Rihova Polymeric anticancer drugs with pH-controlled activation Int J Pharm 277 2004 63 72 (Pubitemid 38670421)
13. R. Duncan, S. Gac-Breton, R. Keane, R. Musila, Y.N. Sat, and R. Satchi Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic J Control Release 74 2001 135 146 (Pubitemid 32727616)
14. M. Kovar, T. Mrkvan, J. Strohalm, T. Etrych, K. Ulbrich, and M. Stastny HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia J Controlled Release 92 2003 315 330 (Pubitemid 38372094)
15. K. Abdellaoui, M. Boustta, M. Vert, H. Morjani, and M. Manfait Metabolite-derived artificial polymers designed for drug targeting, cell penetration and bioresorption Eur J Pharm Sci 6 1998 61 73 (Pubitemid 28035226)
16. P.A. Vasey, S.B. Kaye, R. Morrison, C. Twelves, P. Wilson, and R. Duncan Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee Clin Cancer Res 5 1999 83 94 (Pubitemid 29045181)
17. D.K. Armstrong, G.F. Fleming, M. Markman, and H.H. Bailey A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study Gynecol Oncol 103 2006 391 396 (Pubitemid 44604492)
18. Cheng C, Xue W, Diao H, Xia S, Zuo L, He A, et al. Antitumor activity and toxicological properties of doxorubicin conjugated to [alpha],[beta]-poly[(2- hydroxyethyl)-L-aspartamide] administered intraperitoneally in mice. Anticancer Drugs 21:362-71.
19. V. Vassileva, J. Grant, R. De Souza, C. Allen, and M. Piquette-Miller Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model Cancer Chemother Pharmacol 60 2007 907 914 (Pubitemid 47389398)
20. V. Vassileva, E.H. Moriyama, R. De Souza, J. Grant, C.J. Allen, and B.C. Wilson Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging Br J Cancer 99 2008 2037 2043
21. S. Gautier, M. Boustta, and M. Vert Alkylated poly(L-lysine citramide) as models to investigate the ability of amphiphilic macromolecular drug carriers to physically entrap lipophilic compounds in aqueous media J Control Release 60 1999 235 247 (Pubitemid 29335949)
22. P.E. Colombo, M. Boustta, S. Poujol, F. Pinguet, P. Rouanet, and F. Bressolle Biodistribution of doxorubicin-alkylated poly(L-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration Eur J Pharm Sci 31 2007 43 52 (Pubitemid 46604790)
23. A.C. Couffin-Hoarau, M. Boustta, and M. Vert Enlarging the library of poly-(L-lysine citramide) polyelectrolytic drug carriers J Polym Sci 39 2001 3475 3484 (Pubitemid 32975419)
24. E. Configliacchi, G. Razzano, V. Rizzo, and A. Vigevani HPLC methods for the determination of bound and free doxorubicin, and of bound and free galactosamine, in methacrylamide polymer-drug conjugates J Pharm Biomed Anal 15 1996 123 129 (Pubitemid 26323637)
25. D. Fraier, E. Frigerio, E. Pianezzola, B.M. Strolin, J. Cassidy, and P. Vasey A sensitive procedure for the quantitation of free and N-(2-hydroxypropyl) methacrylamide polymer-bound doxorubicin (PK1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone and doxorubicinone, in human plasma and urine by reversed-phase HPLC with fluorimetric detection J Pharm Biomed Anal 13 1995 625 633
26. P. Balaguer, A.M. Boussioux, E. Demirpence, and J.C. Nicolas Reporter cell lines are useful tools for monitoring biological activity of nuclear receptor ligands Luminescence 16 2001 153 158 (Pubitemid 33620713)
27. A. Pillon, N. Servant, F. Vignon, P. Balaguer, and J.C. Nicolas In vivo bioluminescence imaging to evaluate estrogenic activities of endocrine disrupters Anal Biochem 340 2005 295 302 (Pubitemid 40544869)
28. Laboratory animal welfare; U.S. government principles for the utilization and care of vertebrate animals used in testing, research and training; notice Fed Regist 50 1985 20864 20865
29. N. Alvarez-Rueda, M.Z. Ladjemi, G. Behar, S. Corgnac, M. Pugniere, and F. Roquet A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: immunogenicity and efficacy Vaccine 27 2009 4826 4833
30. C.E. McCulloch, and S.R. Searle Generalized, linear, and mixed models 2001 Wiley-Interscience New York, NY
31. N.M. Laird, and J.H. Ware Random-effects models for longitudinal data Biometrics 38 1982 963 974
32. M. Markman, B.N. Bundy, D.S. Alberts, J.M. Fowler, D.L. Clark-Pearson, and L.F. Carson Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J Clin Oncol 19 2001 1001 1007 (Pubitemid 32176274)
33. N. Plaisant, F. Quenet, M. Fabbro, S. Gourgou, M. Gutowski, and B. Saint-Aubert Secondary debulking surgery and intraperitoneal chemotherapy in advanced or recurrent epithelial ovarian cancer Gynecol Obstet Fertil 32 2004 391 397 (Pubitemid 38765989)
34. P.H. Sugarbaker, J.T. Mora, P. Carmignani, O.A. Stuart, and D. Yoo Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy Oncologist 10 2005 112 122 (Pubitemid 40261950)
35. P. Jacquet, A. Averbach, O.A. Stuart, D. Chang, and P.H. Sugarbaker Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model Cancer Chemother Pharmacol 41 1998 147 154 (Pubitemid 28096269)
36. K. Van der Speeten, O.A. Stuart, H. Mahteme, and P.H. Sugarbaker A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin Cancer Chemother Pharmacol 63 2009 799 805
37. C.R. Rossi, S. Mocellin, P. Pilati, M. Foletto, L. Quintieri, and P. Palatini Pharmacokinetics of intraperitoneal cisplatin and doxorubicin Surg Oncol Clin N Am 12 2003 781 794 (Pubitemid 36920099)
38. C. Manzotti, R.A. Audisio, and G. Pratesi Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion Clin Exp Metastasis 11 1993 5 14 (Pubitemid 23045685)
39. X. Fu, and R.M. Hoffman Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens Anticancer Res 13 1993 283 286 (Pubitemid 23196757)
40. C.P. Klerk, R.M. Overmeer, T.M. Niers, H.H. Versteeg, D.J. Richel, and T. Buckle Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals Biotechniques 43 2007 7 13 30
41. D.E. Jenkins, Y. Oei, Y.S. Hornig, S.F. Yu, J. Dusich, and T. Purchio Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis Clin Exp Metastasis 20 2003 733 744 (Pubitemid 38019275)
42. H.M. Buchhorn, C. Seidl, R. Beck, D. Saur, C. Apostolidis, and A. Morgenstern Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging Eur J Nucl Med Mol Imaging 34 2007 841 849 (Pubitemid 46798953)
43. M. Toyoshima, Y. Tanaka, M. Matumoto, M. Yamazaki, S. Nagase, and K. Sugamura Generation of a syngeneic mouse model to study the intraperitoneal dissemination of ovarian cancer with in vivo luciferase imaging Luminescence 24 2009 324 331
44. S. Zeamari, G. Rumping, B. Floot, S. Lyons, and F.A. Stewart In vivo bioluminescence imaging of locally disseminated colon carcinoma in rats Br J Cancer 90 2004 1259 1264 (Pubitemid 38496822)
45. D. Kim, Z.G. Gao, E.S. Lee, and Y.H. Bae In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer Mol Pharm 6 2009 1353 1362
46. L. Zhou, R. Cheng, H. Tao, S. Ma, W. Guo, and F. Meng Endosomal pH-activatable poly(ethylene oxide)-graft-doxorubicin prodrugs: synthesis, drug release, and biodistribution in tumor-bearing mice Biomacromolecules 2011
47. R.F. Ozols, G.Y. Locker, J.H. Doroshow, K.R. Grotzinger, C.E. Myers, and R.I. Fisher Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin Cancer Treat Rep 63 1979 269 273 (Pubitemid 9151513)